Fig. 1From: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysisKaplan–Meier graph depicting time to complete TMA response. BL baseline, TMA thrombotic microangiopathyBack to article page